Want to see SBFM full AI Analyst Report?
SBFM Stock Chart & Stats
$1.66
$0.01(0.89%)
At close: 4:00 PM EDT
$1.66
$0.01(0.89%)
Day’s Range― - ―
52-Week Range$1.10 - $24.30
Previous CloseN/A
Volume3.02K
Average Volume (3M)1.09M
Market Cap
$2.78M
Enterprise Value-$5.11M
Total Cash (Recent Filing)$6.91M
Total Debt (Recent Filing)$744.84K
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Aug 05, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-87.00
Shares Outstanding2,378,317
10 Day Avg. Volume3,175,467
30 Day Avg. Volume1,091,586
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.14
P/FCF Ratio-0.93
Enterprise Value/Market Cap-1.84
Enterprise Value/Revenue-0.14
Enterprise Value/Gross Profit-0.44
Enterprise Value/Ebitda0.91
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.3
Revenue Forecast (FY)$35.40M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageSunshine Biopharma's very low debt-to-equity (~0.03–0.04) and minimal absolute debt reduce balance-sheet insolvency risk and interest burden. This durable capital structure gives management flexibility to pursue product approvals or scale generics without near-term debt pressure, supporting multi-month strategic execution.
Canadian Commercial Foothold Via Nora PharmaRegulatory approval for generic ondansetron and an owned Canadian distribution network (Nora Pharma) create a sustainable commercial channel in oncology supportive care. Adding an on-market generic strengthens recurring revenue potential, leverages existing logistics, and materially expands the company's addressable market over coming quarters.
Stable Product-level Gross Margins And Scaled Revenue BaseConsistent gross margins near 31–35% suggest product and manufacturing economics are intact. Combined with historically scaled revenue versus earlier years, these durable unit economics mean the company can potentially reach profitability if SG&A and R&D are controlled and commercial traction continues, supporting a multi-month recovery path.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicates the business burns cash to sustain operations and development. Over 2–6 months this forces dependence on external funding, constrains reinvestment in commercial scale-up or R&D, and increases execution risk if capital markets tighten or approvals delay revenue realization.
Reliance On Dilutive Equity FinancingThe company's recent $6M unit offering and board approval to issue >20% of shares at a discount show structural reliance on equity markets to fund operations. Repeated dilution reduces shareholder capital per share and signals limited internal cash generation, which can limit long-term investor alignment and increase cost of future capital.
Choppy Revenue And Unconverted ScaleRevenue growth has become uneven—recent TTM declines after modest 2025 growth—and scale has not produced positive operating margins. This indicates structural challenges in converting sales into sustainable profits, meaning earnings recovery depends on sustained volume growth or material cost reduction over the next several quarters.
Sunshine Biopharma News
SBFM FAQ
What was Sunshine Biopharma’s price range in the past 12 months?
Sunshine Biopharma lowest stock price was $1.10 and its highest was $24.30 in the past 12 months.
What is Sunshine Biopharma’s market cap?
Sunshine Biopharma’s market cap is $2.78M.
When is Sunshine Biopharma’s upcoming earnings report date?
Sunshine Biopharma’s upcoming earnings report date is Aug 05, 2026 which is in 3 days.
How were Sunshine Biopharma’s earnings last quarter?
Sunshine Biopharma released its earnings results on May 14, 2026. The company reported -$2.5 earnings per share for the quarter, the consensus estimate of -$2.5 by $0.
Is Sunshine Biopharma overvalued?
According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued.
Does Sunshine Biopharma pay dividends?
Sunshine Biopharma does not currently pay dividends.
What is Sunshine Biopharma’s EPS estimate?
Sunshine Biopharma’s EPS estimate is -1.2.
How many shares outstanding does Sunshine Biopharma have?
Sunshine Biopharma has 2,378,317 shares outstanding.
What happened to Sunshine Biopharma’s price movement after its last earnings report?
Sunshine Biopharma reported an EPS of -$2.5 in its last earnings report, expectations of -$2.5. Following the earnings report the stock price went down -28.905%.
Which hedge fund is a major shareholder of Sunshine Biopharma?
Currently, no hedge funds are holding shares in SBFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sunshine Biopharma
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Technical Analysis
Sonoma Pharmaceuticals
―
―
cbdMD
―
IM Cannabis Corp
―
Shuttle Pharmaceuticals Holdings, Inc.
―